Background: Interleukin-1 (IL-1) blockade seems to improve anaerobic exercise in patients with systolic heart failure through improved left ventricular (LV) systolic performance. However, it is unclear whether IL-1 blockade affects LV systolic performance.
INTRODUCTION
Left ventricular (LV) systolic dysfunction is the predominant cardiac impairment in half of all patients with heart failure (HF). 1 Interleukin-1 (IL-1) is a proinflammatory cytokine that improves LV systolic performance in murine HF as measured by LV fractional shortening and ejection fraction. 2 Currently available inotropes, such as dopamine, increase oxygen consumption and have been associated with increased mortality. 3 Therefore, we sought to determine the effect of IL-1 blockade on LV systolic performance and calculated myocardial pressure-volume area (PVA), an established surrogate of cardiac oxygen consumption, in patients with systolic HF.
METHODS
The Virginia Commonwealth University Institutional Review Board approved of the study, which was conducted according to International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki. All patients provided written informed consent before study enrollment.
Patients
We pooled patients from 2 separate clinical trials of IL-1 blockade in systolic HF. 4, 5 In one trial, patients received anakinra 100 mg twice daily for 3 days followed by 100 mg once daily for 11 days. In the second trial, anakinra patients received 100 mg daily for 12 weeks, 4 weeks, or placebo. This analysis is based on only the initial 2 weeks of treatment for patients who received 12 weeks of treatment. We pooled patients from each trial who received anakinra and those who received placebo into distinct groups.
LV Performance Measures
We assessed left ventricular ejection fraction (LVEF) and LV end-systolic elastance (E es ) as measures of LV systolic performance. 6, 7 LVEF was measured according to Simpson's method as recommended for clinical trials. 8 Doppler echocardiography was performed by a blinded cardiologist with images recaptured as necessary to achieve acceptable quality. All measurements were subsequently performed by 2 separate operators blinded to group allocations after study completion. The average of the 2 measurements was used for measures differing #10%, whereas those with .10% were reviewed and discussed to achieve consensus.
LVE es is a load-independent measure of contractility 7,9 and was estimated as the slope of the LV end-systolic pressure (LVESP)-volume relationship and calculated by dividing LVESP by LV end-systolic volume. 6 LVESP was estimated as 0.9 · brachial artery systolic blood pressure. Arterial elastance (LV Ea ) is a measure of LV afterload and was calculated as LVESP divided by LV stroke volume. 6 Systolic blood pressure, stroke volume, and heart rate were measured after 5 minutes of rest over a 1-minute period using a noninvasive continuous hemodynamic monitor (NexfinCC, Edwards Lifesciences, Irvine, CA), and the averaged value was used for LV performance calculations. This monitor calculates brachial artery blood pressure and LV stroke volume based on fingertip capillary pressure waveforms. 10 Myocardial oxygen consumption and LV PVA have been shown to be linearly related. 11 We estimated PVA, the sum of stroke work and potential energy, where potential energy is estimated as 1/2 LV end-systolic volume · LVESP. 6, 7 LV stroke work was estimated as stroke volume · LVESP. 6, 7 Myocardial work efficiency was estimated as stroke work divided by PVA.
Statistical Analysis
Summary statistics are provided as number (%) for categorical variables and median (interquartile range) for continuous variables. Baseline characteristics were compared between anakinra and placebo groups using the x 2 test for categorical variables and the Mann-Whitney U test for continuous variables. Within-group change was tested with the Wilcoxon ranked sum test and between-group change with the Mann-Whitney U test. A P value ,0.05 was considered statistically significant. Correlations between continuous variables were assessed with Spearman's rho. Statistical analysis was conducted with SPSS 24.0 (IBM, Armonck, NY).
RESULTS

Patient Characteristics
The pooled cohort included 48 patients randomized to anakinra and 32 to placebo. There were no significant between-group differences in clinical characteristics, guideline-directed medications, or LV systolic performance measures (see Tables 1 and 2 , Supplemental Digital Content 1, 2, http://links.lww.com/JCVP/A318).
LV Systolic Performance
We did not detect a significant change in LVEF or LVE es between baseline and day 14 in the placebo group (P . 0.22 for each) (Fig. 1) . In the anakinra group, LVEF increased from 30% (24%-38%) to 36% (29%-43%) between baseline and day 14 (P = 0.03 for within-group change and P = 0.02 for between-group change compared with placebo) (Fig. 1) . LVE es increased from 1.0 mm Hg/ mL (0.7-1.5) to 1.3 mm Hg/mL (0.8-1.6) between baseline and day 14 in anakinra-treated patients (P = 0.03 for withingroup change and P = 0.08 for between-group change). A change in PVA between baseline and 14 days was not detected in either anakinra or placebo patients (see Table 2 , Supplemental Digital Content 2, http://links.lww.com/ JCVP/A318).
In anakinra-treated patients, the median change in heart rate was 24 beats per minute (213 to 3; P = 0.01 for withingroup change) and for the placebo arm was 1 beat per minute (25 to 6; P = 0.97 for within-group change) (P = 0.17 for between-group change). For the anakinra patients, median LV Ea was 1.56 (1.35-1.99) mm Hg/mL at baseline and 1.56 (1.34-1.94) mm Hg/mL at 14 days (P = 0.35). In the placebo arm, median LV Ea was 1.78 (1.47-2.35) mm Hg/mL at baseline and 1.66 (1.50-2.58) mm Hg/mL at 14 days (P = 0.33) (P = 0.55 for between-group comparison).
DISCUSSION
In this study, we found that the increase in LV systolic performance with IL-1 blockade was not accompanied by a signal for increased myocardial work or oxygen consumption. Considering the adverse effects of catecholaminergic inotropes on myocardial oxygen consumption, the relationship between IL-1 blockade and oxygen consumption in patients with HF is an important concern.
We included 2 measures of LV systolic performance: LVEF and LVE es . LVEF can be readily measured in routine practice but changes in LVEF may reflect alterations in cardiac load or in contractility. By contrast, LVE es is a loadindependent measure of LV contractility. 7, 9 Thus, the fact that both distinct measures suggest that anakinra improves LV systolic performance and increases our confidence in the results of this small pilot study. Resting heart rate significantly declined in anakinratreated patients. Improvements in LV systolic function in the anakinra arm may have permitted cardiac output to remain sufficient for the body's needs without an elevated heart rate. There was no detectable difference in heart rate in the placebo arm, which may be attributable to our small sample size or short measurement interval. Anakinra did not have an observable effect on LV afterload, measured as LV Ea , which suggests that anakinra' effects on LV systolic performance may be found to be load independent, pending validation in a larger cohort.
In this analysis, IL-1 blockade as a strategy exhibits a favorable safety profile. Daily subcutaneous administration of anakinra provokes an injection site reaction in many patients, and therefore, chronic IL-1 blockade with longerlasting antibodies may be a preferred strategy.
IL-1 blockade represents a distinct mechanism of action from existing inotropes, which increase myocardial oxygen consumption, promote arrhythmias, and are associated with worse survival. 3 Proarrhythmic effects have not been observed in clinical trials of IL-1 blockade, and IL-1 blockade prevented arrhythmias in a preclinical animal model. 5, 12, 13 Thus, IL-1 blockade seems to overcome several safety concerns with current positive inotropes. The effects of IL-1 blockade on clinical outcomes remain to be determined, although ongoing clinical trials suggest an improvement in aerobic exercise capacity and a trend toward fewer hospitalizations. 5 
Limitations
This proof-of-concept analysis has certain limitations. It was a post hoc analysis conducted using noninvasive cardiac measurements in which we assumed a linear slope of the ESPvolume relationship and a volume-axis intercept (V 0 ) = 0. We did not alter loading conditions and measured only a single point on the ESP-volume relationship. We assessed LV systolic function at rest but not during exercise. Hemodynamic measurements were averaged over a short (1-minute) interval and, despite best efforts to minimize variability by resting the patient and eliminating distractions, we may have introduced unnecessary variability into our measurements. We combined results from clinical trials with different designs and had a small sample size. Although PVA is an established surrogate of oxygen consumption, we did not measure invasively PVA but rather calculated an estimate. These results improve our understanding of IL-1 blockade in patients with HF and may inform the design of the larger outcomes trials necessary to determine the clinical efficacy of IL-1 blockade.
CONCLUSIONS
In summary, we found that IL-1 blockade improved LV systolic performance. We did not detect an effect of IL-1 blockade on myocardial PVA. IL-1 blockade's effects on systolic performance seem to be distinct from classic inotropes, and therefore, this strategy may have an improved safety profile.
